可生物降解固体脂质纳米粒的制备、表征及药物的体外释放

以可生物降解材料硬脂酸为载体, 以葛根总黄酮为模型药物, 采用乳化蒸发-低温固化法制备固体脂质纳米粒. 采用透射电镜研究载药纳米粒形态, 激光粒度分析仪测定其粒径, X射线衍射仪进行物相鉴别, 并对纳米粒的包封率及体外释药特性等进行了研究. 分析结果表明, 所制备硬脂酸固态脂质纳米粒为类球实体, 粒径分布比较均匀, 平均粒径为(263.82±3.6) nm, 包封率为(67.53±0.12)%. X射线衍射分析证明药物以分子或细小粒子分散于脂质骨架中. 体外释药研究结果表明, 纳米粒体外释药先快后慢, 12 h累积释药50%, 包封于降解材料骨架内的药物通过骨架溶蚀缓慢释放. 药物的体外释放符合Higuchi方程.     

应用于药物传输系统的聚合物纳米粒

载药聚合物纳米粒具有良好的组织靶向性和缓控释性，本文简要介绍了聚合物纳米粒在药物传输系统中的特点，综合分析并讨论了纳米粒的制备技术及应用，展望了今后的研究方向。     

聚合物纳米粒应用于透皮给药及促渗机制研究进展

透皮给药系统因具有避免肝脏首过效应、血药浓度稳定、局部靶向性及给药方便等优势而备受青睐。然而角质层作为一种生物屏障限制了很多药物,特别是亲水性药物的经皮渗透,因此采用有效的方法促进药物经皮渗透成为透皮给药的关键。聚合物纳米粒因具有药物包封率高、减小酶降解、可控释性能好、比表面积大等优势,易于在皮肤表面富集,从而促进药物渗透,其作为药物载体用于透皮给药逐渐成为近几年的研究热点。本文综述了近年来纳米粒在促进药物渗透方面的研究进展,包括纳米粒促进药物渗透的机制,以及纳米粒联合主动透皮给药方式在促进药物经皮渗透中的应用,并对研究中存在的问题提出适当建议。     

水凝胶纳米粒及其在生物医药领域的应用

作为环境响应性和纳米控释给药系统，水凝胶纳米粒主要用于毒副作用大、生物半衰期短、易被生物酶降解的多肽类、蛋白质等生物大分子药物的给药，在生物医药领域具有越来越广阔的应用前景。本文主要综述了水凝胶纳米粒的分类、制备方法及其在生物医药领域的应用。     

叶酸靶向乙酰普鲁兰纳米粒的制备及其靶向作用

以普鲁兰多糖为主链, 通过乙酰化反应合成了疏水性的乙酰普鲁兰(PA), 然后以N,N′-二环己基碳二亚胺(DCC)为偶联剂, 4-二甲氨基吡啶(DMAP)为催化剂, 将叶酸与PA偶联(FPA); 采用¹H NMR和X射线晶体衍射(XRD)等方法对产物结构进行了表征. 采用溶剂扩散法制备包载表阿霉素的PA和FPA纳米粒, 载药纳米粒形态为球形, 动态光散射粒径分析显示载药纳米粒粒径随载药量增加而增大. 透析法测定纳米粒中表阿霉素的体外释放表明, FPA纳米粒中药物释放速度快于PA纳米粒; 采用激光共聚焦显微镜观察PA/EPI及FPA/EPI纳米粒在KB细胞的摄取情况, 结果表明, FPA/EPI纳米粒进入细胞主要通过叶酸受体途径, 而PA/EPI纳米粒进入细胞与叶酸受体无关, 提示FPA将成为具有一定肿瘤靶向作用的新型载体.     

肝靶向海藻酸钠载药纳米粒的细胞毒性研究

本研究将具有肝靶向性分子甘草次酸（GA）偶联在具有生物相容性和生物可降解性的天然高分子海藻酸钠（ALG）上,合成了甘草次酸改性的海藻酸钠（GA—ALG）;对广谱抗癌药物阿霉素（DOX）进行包封,制备了肝靶向载药纳米粒,并考察了GA—ALG载药纳米粒的体外释药性能和对肝癌细胞的抑制作用．利用核磁、红外和元素分析技术对GA—ALG结构和GA取代度进行了表征;对GA—ALG载药纳米粒的形貌、粒径、表面Zeta电位等进行了测定,结果显示纳米粒具有较规则球形结构,其水合粒径为（214±11）nm．GA—ALG载药纳米粒在模拟生理条件下（pH7．4）可持续释药长达20天;MTT结果显示GA-ALG载药纳米粒对7703肝癌细胞的具有明显的杀伤作用．     

脂质组成对硫辛酸脂质纳米粒的制备及其稳定性的影响

采用高压均质法制备硫辛酸(ALA)脂质纳米粒(ALA-NLC),确定了负载ALA的最佳体系。通过高效液相色谱、动态光散射、流变等测试研究了脂质成分、含量对ALA负载、ALA-NLC稳定性和分散液流变性质的影响,并用原子力显微镜观察了ALA-NLC的形貌。结果表明,脂质/ALA质量比在4.5∶1～6∶1之间,得到的脂质纳米粒分散均匀,颗粒规则;脂质中液态油脂的增加有利于保持ALA-NLC的粒径,储存稳定性和分散液的低粘度,并得到两个有望用于食品工业的ALA-NLC配方。     

高效液相色谱法测定紫杉醇及其脂质纳米粒包封率的方法学研究

建立了一种对本实验室研制的新型载带紫杉醇脂质纳米载体(nanostructured lipid carriers,NLC)进行定性定量分析的新方法,并计算紫杉醇的包封率.用反相高效液相色谱法进行测定.采用C18柱对未纯化的紫杉醇脂质纳米粒进行分离检测,梯度法分离,流动相为水和乙腈,紫外检测器波长为227 nm,荧光检测器激发波长为428 nm,发射波长为515 nm.结果表明梯度法对紫杉醇脂质纳米粒和游离紫杉醇的分离效果良好,辅料和试剂无干扰,紫杉醇在3.0～80.0 mg/L之间有良好的线性关系,线性方程为:Y=42100ρ 8250,r=0.9999,日内RSD为0.15%(n=5),日间RSD为0.25%(n=4),平均回收率为109.09%,RSD为0.12%,通过本方法,测定的紫杉醇纳米粒平均包封率为68.78%.本法可对紫杉醇进行定量分析,也可对紫杉醇脂质纳米粒制剂进行定性和定量分析,可以直接测量计算其包封率.     

基于磁性氧化铁纳米粒的诊断治疗药物

诊断治疗药物作为一种新兴的治疗策略,展现出良好的应用前景。基于磁性氧化铁纳米粒的诊断治疗药物利用纳米技术将纳米粒与治疗性药物同时装载于纳米粒上,该纳米系统一般由三部分组成:磁性纳米粒核心、包覆层及功能区域。该系统可以用于影像诊断、实时监测药物输送、进行药效评价,并有望用于个体化医疗。本文介绍了磁性氧化铁纳米粒的合成、表面修饰、功能化及其生物医学应用等,重点介绍了磁性氧化铁纳米粒的表面修饰及功能化,经过表面修饰及功能化后,可制得多模式化、多功能化的诊断治疗药物,并对纳米诊断治疗药物在应用于个体化医疗所面临的挑战进行了初步的分析讨论。     

普鲁兰多糖的硬脂酸修饰及其作为纳米药物载体的研究

利用1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC)和4-二甲氨基吡啶(DMAP)催化硬脂酸(SA)与具有良好生物相容性的普鲁兰多糖(Pullulan)反应, 将硬脂酸接枝在普鲁兰分子链的羟基上, 得到取代度不同的疏水改性两亲性普鲁兰多糖衍生物PUSA1, PUSA2 及PUSA3, 其临界胶束浓度分别为50, 32, 18 μg/mL; 透射电镜(TEM)图像显示透析法制备的PUSA 自组装颗粒为球形. 以阿霉素为模型药物制备了PUSA 载药纳米粒, 考察了载药纳米粒的载药量、包封率和体外药物释放. 结果表明PUSA3 的包封率高达84%, 载药量达7.79%. 药物可在37 ℃, pH＝7.4 的PBS 溶液中持续释放90 h 以上. 细胞毒性实验(MTT)结果显示当PUSA 的浓度高达1000 μg/mL 时48 h 后细胞存活率依然在90%左右. 流式细胞及荧光分析表明载药纳米粒的细胞摄取率远远高于游离药物. 说明PUSA 是一种新型的有潜在应用价值的药物载体材料.     

Cubosomes: The Next Generation of Smart Lipid Nanoparticles?

Cubosomes are highly stable nanoparticles formed from the lipid cubic phase and stabilized by a polymer based outer corona. Bicontinuous lipid cubic phases consist of a single lipid bilayer that forms a continuous periodic membrane lattice structure with pores formed by two interwoven water channels. Cubosome composition can be tuned to engineer pore sizes or include bioactive lipids, the polymer outer corona can be used for targeting and they are highly stable under physiological conditions. Compared to liposomes, the structure provides a significantly higher membrane surface area for loading of membrane proteins and small drug molecules. Owing to recent advances, they can be engineered in vitro in both bulk and nanoparticle formats with applications including drug delivery, membrane bioreactors, artificial cells, and biosensors. This review outlines recent advances in cubosome technology enabling their application and provides guidelines for the rational design of new systems for biomedical applications.     

Primary investigation of the preparation of nanoparticles by precipitation

The absorption, distribution, biotransformation and excretion of a drug involve its transport across cell membranes. This process is essential and influenced by the characteristics of the drug, especially its molecular size and shape, solubility at the site of its absorption, relative lipid solubility, etc. One of the progressive ways for increasing bioavaibility is a nanoparticle preparation technique. Cholesterol, cholestenolone and pregnenolone acetate as model active pharmaceutical ingredients and some of the commonly used excipients as nanoparticle stabilizers were used in the investigated precipitation method that was modified and simplified and can be used as an effective and an affordable technique for the preparation of nanoparticles. All 120 prepared samples were analyzed by means of dynamic light scattering (Nanophox). The range of the particle size of the determined 100 nanoparticle samples was from 1 nm to 773 nm, whereas 82 samples contained nanoparticles of less than 200 nm. Relationships between solvents and used excipients and their amount are discussed.     

Application of TPGS in polymeric nanoparticulate drug delivery system

d-alpha-Tocopheryl polyethylene glycol 1000 succinate (TPGS) has great potential in pharmacology and nanotechnology. The present work investigated the molecular behaviour of TPGS at the air-water interface, its effect on a model bio-membrane composed of dipalmitoylphosphatidylcholine (DPPC) lipid monolayer, and the interaction between the TPGS coated nanoparticles with the lipid model membrane. Paclitaxel loaded polymeric nanoparticles with TPGS as surfactant stabiliser were fabricated and characterised in terms of their drug incorporation capability and release kinetics. The result showed that TPGS exhibited notable effect on the surface properties of air-water interface as well as the lipid monolayer. The inter-particle force and the interaction between nanoparticles and lipid monolayer varied with the surface substance. The penetration of various nanoparticles into the model membrane indicated that an optimal balance between hydrophilicity and hydrophobicity on nanoparticle surface is needed to achieve an effective cellular uptake of nanoparticles. The results also demonstrate that the drug incorporation capability and the release characteristics of drug-loaded nanoparticles can be influenced by surfactant stabiliser.     

Investigation of Drug Nanoparticle Formation by Co-grinding with Cyclodextrins: Studies for Indomethacin, Furosemide and Naproxen

Drugs with poor water solubility were co-ground with cyclodextrins (CDs) to create nanoparticles with improved solubility characteristics. Indomethacin (IDM), furosemide (FRM) and naproxen (NAP) were co-ground with β-CD at the molar ratio of 2:1 (CD:drug). Co-grinding of a drug with CD resulted in not only the formation of drug nanoparticles but also the solubilization of the drug by inclusion complex formation with CD in aqueous media. The nanoparticle fraction of IDM, and FRM from ground mixtures prepared with β-CD was as high as 60–70% while the solubilization fraction was less than 10%. In contrast, β-CD–NAP ground mixture showed a large fraction, 48%, for drug solubilization and only 4% for nanoparticle formation. Furosemide ground mixtures prepared with α-CD, β-CD and γ-CD showed comparatively high nanoparticle fraction while the solubilization fraction was around 10%. Both the nanoparticle fraction and the solubilization fraction were greater in the IDM–β-CD system than those in γ-CD and α-CD systems. The nanoparticle formation of NAP depended on the types of CD used as a co-grinding additive. Naproxen nanoparticles could be prepared by co-grinding NAP and α-CD, while the solubilization of NAP tended to improve when β-CD or γ-CD was used.     

Hybrid Nanoparticles as Drug Carriers for Controlled Chemotherapy of Cancer

Rapid developments in materials science and biological mechanisms have greatly boosted the research discoveries of new drug delivery systems. In the past few decades, hundreds of nanoparticle‐based drug carriers have been reported almost on a daily basis, in which new materials, structures, and mechanisms are proposed and evaluated. Standing out among the drug carriers, the hybrid nanoparticle systems offer a great opportunity for the optimization and improvement of conventional chemotherapy. By combining several features of functional components, these hybrid nanoparticles have shown excellent promises of improved biosafety, biocompatibility, multifunctionality, biodegradability, and so forth. In this Personal Account, we highlight the recent research advances of some representative hybrid nanoparticles as drug delivery systems and discuss their design strategies and responsive mechanisms for controlled drug delivery.     

Surface-modulated and thermoresponsive polyphosphoesternanoparticles for enhanced intracellular drug delivery

The chemical structure of end groups influenced the phase transition temperature of thermoresponsive polymers. We demonstrated a strategy for the preparation of the pH/thermo-responsive polymeric nanoparticles via subtle modification of end groups of thermoresponsive polymer segments with a carboxyl group and revealed its potential application for enhanced intracellular drug delivery. By developing a polymeric nanoparticle composed of poly(aliphatic ester) as the inner core and thermoresponsive polyphosphoester as the outer shell, we showed that end groups of thermoresponsive polyphosphoester segments modified by carboxyl groups exhibited a pH/thermo-responsive behavior due to the hydrophilic to hydrophobic transitions of the end groups in response to the pH. Moreover, by encapsulating doxorubicin into the hydrophobic core of such pH/thermo-responsive polymer nanoparticles, their intracellular delivery and cytotoxicity to wild-type and drug-resistant tumor cells were significantly enhanced through the phase-transition-dependent drug release that was triggered by endosomal/lysosomal pH. This novel strategy and the multi-responsive polymer nanoparticles achieved by the subtle chain-terminal modification of thermoresponsive polymers provide a smart platform for biomedical applications.     

基于纳米囊泡的原位凝胶系统

构建了纳米囊泡的原位凝胶系统. 以卵磷脂(PC)和胆固醇(CH)为纳米囊脂质材料, 按m(PC):m(CH)=3:1及m(脂质材料):m(药物)=5:1称取PC, CH和药物, 溶于无水乙醚作为有机相, 以质量分数为0.5%的吐温-80的磷酸盐(pH=7.4)缓冲液为水相(有机相与水相体积比为1.5:1), 采用薄膜分散-高压均质法制备了叶黄素纳米囊泡. 将普朗尼克F127(F127)和普朗尼克F68(F68)分散于纳米囊泡中水化, 制备了纳米囊泡原位凝胶系统. 以试管倒置法测定人工泪液和添加剂对F127-F68纳米囊泡原位凝胶系统胶凝温度的影响; 采用流变学研究了系统升温过程中溶胶-凝胶转变过程及上述辅料对该转变过程的影响; 分别以无膜溶蚀法和高效液相色谱(HPLC)法探讨了系统的体外溶蚀动力学和体外释药行为. 结果表明, 优化的纳米囊泡凝胶系统在25 ℃呈溶液态, 在眼部微环境下形成凝胶, 且药物释放及凝胶溶蚀均以恒定的速率进行, 为零级动力学特征.     

基于生物大分子的纳米药物载体

生物大分子材料由于其可再生性、无毒性以及良好的生物相容性、生物可降解性和黏膜粘附性等特点成为药物载体研究的热点,尤其是将其作为纳米药物载体材料更加受人关注。本文首先对生物大分子纳米颗粒常用的制备方法--乳化法、自组装法和离子凝聚法进行了详细的介绍。由于乳化法在一定程度上破坏了生物大分子的生物相容性,因此自组装法和离子凝聚法是比较理想的制备方法。其中自组装法是利用两亲性的生物大分子,如蛋白质、多糖衍生物等在静电作用、疏水作用、范德华力等非键合作用力下组装成纳米结构;而离子凝聚法则是利用聚电解质与带相反电荷物质之间的静电作用形成纳米结构。接着本文对通过这些方法获得的生物大分子纳米颗粒作为蛋白类药物、抗癌药物以及基因药物的载体在近年来的研究进展进行了归纳和总结,结果显示其在药物缓释体系中具有广阔的应用前景。     

基于生物矿化的纳米载药体系

基于生物矿化的纳米载药体系具有制备简单、良好的生物相容性和控制药物释放的能力、易被修饰且具备多功能性和靶向性等优点,在临床中拥有巨大的应用前景。本文系统阐述了基于生物矿化的纳米载体的构建原理和分类,重点介绍了它们的靶向性策略和刺激响应释放策略,并展望了其在临床治疗中的应用。     

基于生物矿化的纳米载药体系

基于生物矿化的纳米载药体系具有制备简单、良好的生物相容性和控制药物释放的能力、易被修饰且具备多功能性和靶向性等优点,在临床中拥有巨大的应用前景。本文系统阐述了基于生物矿化的纳米载体的构建原理和分类,重点介绍了它们的靶向性策略和刺激响应释放策略,并展望了其在临床治疗中的应用。